Vista Pharmaceuticals reported a net loss of ₹98.59 Lakhs for the quarter ended June 30, 2026. The company also disclosed negative working capital of ₹183.32 Lakhs and highlighted ongoing financial challenges, including defaults on bank borrowings and a Non-Performing Asset (NPA) classification of its credit facilities. These factors raise material uncertainty about its ability to continue as a going concern, although management is actively negotiating debt restructuring.
Vista Pharmaceuticals Reports Financial Challenges for Q1 FY27
Vista Pharmaceuticals Limited has announced its unaudited financial results for the quarter ended June 30, 2026, revealing a net loss of ₹98.59 Lakhs. This marks the company’s sixth consecutive year of losses, accompanied by negative working capital. The total comprehensive income for the period stood at (₹97.98) Lakhs.
Key Financial Highlights
- Revenue from operations: Nil for the quarter ended June 30, 2026, compared to ₹151.88 Lakhs in the previous year.
- Loss Before Tax: ₹132.71 Lakhs for the quarter, compared to ₹148.01 Lakhs in the corresponding previous year quarter.
- Net Profit/(Loss) After Tax: ₹(98.59) Lakhs for the quarter, compared to ₹(129.04) Lakhs in the corresponding previous year quarter.
- Total Comprehensive Income: ₹(97.98) Lakhs.
Operational and Financial Concerns
The company’s credit facilities have been classified as a Non-Performing Asset (NPA) by its lender due to a default in debt servicing exceeding 90 days. This has resulted in a freeze on working capital accounts, temporarily constraining operational liquidity. Furthermore, Vista Pharmaceuticals has experienced defaults in repaying principal and interest on its long-term bank borrowings. These financial conditions collectively indicate a material uncertainty that casts significant doubt on the Company’s ability to continue as a going concern.
Despite these challenges, the interim financial results have been prepared on a ‘Going Concern’ basis. Management is actively engaged in negotiating debt restructuring with lenders, implementing cost-rationalisation measures, and has secured formal undertakings from subscribers of convertible share warrants to pay call money amounting to ₹922.49 Lakhs, which is expected to facilitate meeting operational obligations.
Other Disclosures
The company’s operations are consolidated within a single segment, Manufacturing of Pharmaceutical Products, making segmental reporting unnecessary. The detailed financial results are also available on the websites of the Bombay Stock Exchange, the National Stock Exchange, and the Company’s own website.
Source: BSE
